Issue Date: August 1, 2011
Behind The Surge
Since January, the Food & Drug Administration has approved as many new molecular entities, or NMEs, as it did in all of 2010. The statistic has led drug industry watchers to wonder what prompted the seemingly sudden improvement in productivity and to ask whether companies can sustain this pace of new approvals.
A popular explanation for the surge in new drug approvals, or NDAs, is that big drug companies, after a period of R&D . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society